IN8BIO Appoints New CMO, Elects Director
Ticker: INAB · Form: 8-K · Filed: Sep 11, 2024 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 8-K |
| Filed Date | Sep 11, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-election, personnel-change
TL;DR
IN8BIO brings in a new CMO and adds a director to the board.
AI Summary
IN8BIO, INC. announced on September 6, 2024, the appointment of Dr. Lawrence M. Cohen as Chief Medical Officer and the election of Ms. Jennifer L. D. Allison to its Board of Directors. The company also disclosed compensatory arrangements for certain officers, details of which are provided in the filing.
Why It Matters
These executive and board changes can signal shifts in the company's strategic direction and leadership, potentially impacting its future development and operational focus.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- IN8BIO, INC. (company) — Registrant
- Dr. Lawrence M. Cohen (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. D. Allison (person) — Elected to Board of Directors
- September 6, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer for IN8BIO, Inc.?
Dr. Lawrence M. Cohen has been appointed as the Chief Medical Officer for IN8BIO, Inc.
Who was elected to the Board of Directors of IN8BIO, Inc.?
Ms. Jennifer L. D. Allison was elected to the Board of Directors of IN8BIO, Inc.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing is September 6, 2024.
What is the principal executive office address for IN8BIO, Inc.?
The principal executive office address for IN8BIO, Inc. is 350 5th Avenue, Suite 5330, New York, New York 10118.
What is the telephone number for IN8BIO, Inc.?
The telephone number for IN8BIO, Inc. is (646) 600-6438.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-09-11 16:01:54
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share INAB The Nasdaq
Filing Documents
- d853919d8k.htm (8-K) — 23KB
- 0001193125-24-217229.txt ( ) — 145KB
- inab-20240906.xsd (EX-101.SCH) — 3KB
- inab-20240906_lab.xml (EX-101.LAB) — 18KB
- inab-20240906_pre.xml (EX-101.PRE) — 11KB
- d853919d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IN8bio, Inc. Dated: September 11, 2024 By: /s/ Patrick McCall Patrick McCall Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)